Orthopaedic manifestations of glutaric acidemia Type 1
Ahmet Imerci1, Kevin A Strauss2, Geovanny F Oleas-Santillan3
1Department of Orthopaedics and Traumatology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
Insights
Glutaric acidemia type 1 (GA1) patients with neurological injury face musculoskeletal issues like scoliosis and hip dislocation. Early orthopaedic intervention, guided by metabolic specialists, is crucial for managing these complications.
Area of Science:
- Genetics and Metabolic Disorders
- Orthopaedics and Musculoskeletal Health
- Neurology and Neurodevelopmental Disorders
Background:
- Glutaric acidemia type 1 (GA1) is a rare hereditary metabolic disorder.
- It is caused by biallelic mutations in the GCDH gene.
- GA1 can lead to striatal degeneration in early childhood.
Purpose of the Study:
- To review the orthopaedic sequelae in neurologically injured patients with GA1.
- To analyze the management strategies for these musculoskeletal complications.
Main Methods:
- Retrospective chart review of 114 GA1 patients over 28 years.
- Data collection included demographics, comorbidities, muscle tone, GMFCS level, and orthopaedic diagnoses.
- Focus on patients homozygous for the GCDH c.1262C>T founder variant.
Main Results:
- 21% of patients developed musculoskeletal problems requiring orthopaedic consultation.
- Common issues included scoliosis (14 patients) and hip dislocation (8/15 hips).
- 35 orthopaedic surgeries were performed, with proximal femoral osteotomy and spinal fusion being common procedures.
Conclusions:
- GA1 patients with static striatal lesions are prone to musculoskeletal complications.
- Scoliosis and hip dislocation are significant risks.
- Management requires metabolic specialist consultation, focusing on fluid and nutritional support.
Purpose:
Glutaric acidemia type 1 (GA1), a rare hereditary metabolic disease caused by biallelic mutations of GCDH, can result in acute or insidious striatal degeneration within the first few years of life. We reviewed the orthopaedic sequelae and management of 114 neurologically injured patients with a confirmed molecular diagnosis of GA1.
Methods:
We performed a retrospective chart review spanning 28 years identifying 114 GA1 patients, most from the Old Order Amish population of Lancaster County, Pennsylvania, who were homozygous for a pathogenic founder variant of GCDH (c.1262C>T). We collected demographics, medical comorbidities, muscle tone patterns, Gross Motor Function Classification System level, gastrostomy tube status, seizure history, inpatient events, orthopaedic diagnoses and operative characteristics.
Results:
Over an average follow-up of 4.7 ± 3.4 years, 24 (21%) of 114 patients had musculoskeletal problems requiring orthopaedic consultation. Scoliosis (n = 14), hip dislocation (n = 8/15 hips), hip subluxation (n = 2/three hips), and windswept hip deformity (n = 2) in the spine and hip joint were most common. In total, 35 orthopaedic surgeries were performed in 17 (71%) patients. The most common primary operations were one-stage procedures with proximal femoral varus derotation osteotomy and/or pelvic osteotomy (n = 8/14 hips) for subluxation or dislocation. In all, 11 patients had posterior spinal fusion for severe scoliosis. With the recommended metabolic management, there were no disease-specific complications in this cohort.
Conclusions:
Children with GA1 who have static striatal lesions are at risk for musculoskeletal complications, especially scoliosis and hip dislocation, and appropriate operative management requires consultation with a metabolic specialist with specific considerations for fluid management and nutrition.
Level Of Evidence:
IV.
More Related Videos
07:24Autologous Microfractured and Purified Adipose Tissue for Arthroscopic Management of Osteochondral Lesions of the Talus
Published on: January 23, 2018
14:49Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
Related Concept Videos
Inborn Errors of Metabolism
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Proteoglycans
Chronic Kidney Disease II: Clinical Manifestations
Acute Pancreatitis II: Clinical Manifestations and Management
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
